Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series
Adults with sickle cell disease can develop pulmonary hypertension from a multitude of etiologies. Classified as WHO Group 5, there are no therapies approved for the treatment of sickle cell disease-pulmonary hypertension. Thromboembolic disease is prevalent in sickle cell disease and can lead to pu...
Main Authors: | Nargues A. Weir, Anna Conrey, Denise Lewis, Alem Mehari |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-07-01
|
Series: | Pulmonary Circulation |
Online Access: | https://doi.org/10.1177/2045894018791802 |
Similar Items
-
Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: Raymond L. Benza, et al.
Published: (2022-10-01) -
Riociguat is a novel medication for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: N. A. Tsareva, et al.
Published: (2016-12-01) -
Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice
by: Danica Michaličková, et al.
Published: (2020-01-01) -
Riociguat inhibits ultra‐large VWF string formation on pulmonary artery endothelial cells from chronic thromboembolic pulmonary hypertension patients
by: Takayuki Jujo Sanada, et al.
Published: (2022-10-01) -
Combination of rescue balloon pulmonary angioplasty and riociguat therapy for chronic thromboembolic pulmonary hypertension with nonsustained polymorphic ventricular tachycardia: A case report
by: Yoshitake Fukuda, et al.
Published: (2023-07-01)